Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider.

J Neurooncol · 2020 · PMC7316675 · PMID 32409944

Europe PMC DOI

hedged sentences

0.0100

closest p · 0.2× alpha

0.1790

boldest claim

The sentences

highly significantp = 0.010actually significant

10.2 months, p = 0.578), patients with higher-order recurrences showed a marked improvement, which was highly significant (second or higher order of recurrence n = 40, median OS 9.9 vs. 2.6 months, p = 0.010).

also in 132,142 other papers

failed to reach significancep = 0.179not close (p > 0.1)

Additional resection and additional radiotherapy showed a reduced hazard ratio for progression or death but failed to reach significance (PFS, HR = 0.60, p = 0.179 and HR = 0.54, p = 0.073 respectively).

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.